These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 21543938)

  • 21. Other new targets.
    Mackay HJ; Oza AM
    Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2():S49-54. PubMed ID: 19955915
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current and future medical therapy, and the molecular features of adrenocortical cancer.
    Hubalewska-Dydejczyk A; Jabrocka-Hybel A; Pach D; Gilis-Januszewska A; Sokołowski G
    Recent Pat Anticancer Drug Discov; 2012 Jan; 7(1):132-45. PubMed ID: 21854357
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tyrosine-kinases inhibitors in recurrent platinum-resistant ovarian cancer patients.
    Marchetti C; Palaia I; De Felice F; Musella A; Donfracesco C; Vertechy L; Romito A; Piacenti I; Musio D; Muzii L; Tombolini V; Benedetti Panici P
    Cancer Treat Rev; 2016 Jan; 42():41-6. PubMed ID: 26559739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successes and limitations of targeted cancer therapy in ovarian cancer.
    Damia G; Sessa C
    Prog Tumor Res; 2014; 41():89-97. PubMed ID: 24727989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biomarkers in the development of anti-angiogenic therapies for ovarian cancer.
    Raja FA; Hook JM; Ledermann JA
    Cancer Treat Rev; 2012 Oct; 38(6):662-72. PubMed ID: 22209539
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents.
    Falci C; Dieci MV; Guarneri V; Soldà C; Bria E; Tortora G; Conte P
    Expert Rev Anticancer Ther; 2014 Sep; 14(9):1041-50. PubMed ID: 24953376
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Delivering on the promise: poly ADP ribose polymerase inhibition as targeted anticancer therapy.
    OʼSullivan Coyne G; Chen A; Kummar S
    Curr Opin Oncol; 2015 Nov; 27(6):475-81. PubMed ID: 26447876
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resistance to chemotherapy in ovarian carcinoma.
    Lage H; Denkert C
    Recent Results Cancer Res; 2007; 176():51-60. PubMed ID: 17607916
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted agents and combinations in ovarian cancer: where are we now?
    McLachlan J; Lima JP; Dumas L; Banerjee S
    Expert Rev Anticancer Ther; 2016; 16(4):441-54. PubMed ID: 26942837
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Promising targets and drugs in development for colorectal cancer.
    Thompson C; Leong S; Messersmith W
    Semin Oncol; 2011 Aug; 38(4):588-97. PubMed ID: 21810518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted Therapy of Ovarian Cancer with Angiogenesis Inhibitors.
    Duan P; Fan L; Gao Q; Silwal BM; Ren M; Shen Y; Qu W
    Curr Drug Targets; 2017; 18(10):1171-1178. PubMed ID: 28443505
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An overview of early investigational therapies for chemoresistant ovarian cancer.
    Marchetti C; Ledermann JA; Benedetti Panici P
    Expert Opin Investig Drugs; 2015; 24(9):1163-83. PubMed ID: 26206420
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trial design for testing new therapies in ovarian cancer.
    Eisenhauer EA
    Int J Gynecol Cancer; 2005; 15 Suppl 3():258-65. PubMed ID: 16343242
    [No Abstract]   [Full Text] [Related]  

  • 34. Aflibercept in epithelial ovarian carcinoma.
    Moroney JW; Sood AK; Coleman RL
    Future Oncol; 2009 Jun; 5(5):591-600. PubMed ID: 19519199
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.
    Li M; Li H; Liu F; Bi R; Tu X; Chen L; Ye S; Cheng X
    J Ovarian Res; 2017 Feb; 10(1):9. PubMed ID: 28187748
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [First-line chemotherapy in advanced ovarian cancer].
    Colombo N; Parma G; Caspani G; Donesana P; Marinetti E; Mangioni C
    Tumori; 1999; 85(3 Suppl 1):S23-6. PubMed ID: 10542882
    [No Abstract]   [Full Text] [Related]  

  • 37. Novel therapies, including enzastaurin, in the treatment of ovarian cancer.
    Vergote I
    Expert Opin Investig Drugs; 2014 May; 23(5):579-98. PubMed ID: 24654681
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted therapy for epithelial ovarian cancer: current status and future prospects.
    See HT; Kavanagh JJ; Hu W; Bast RC
    Int J Gynecol Cancer; 2003; 13(6):701-34. PubMed ID: 14675307
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemoresistance and targeted therapies in ovarian and endometrial cancers.
    Brasseur K; Gévry N; Asselin E
    Oncotarget; 2017 Jan; 8(3):4008-4042. PubMed ID: 28008141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Therapeutic Potential of Targeting the HGF/cMET Axis in Ovarian Cancer.
    Moran-Jones K
    Mol Diagn Ther; 2016 Jun; 20(3):199-212. PubMed ID: 27139908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.